Homegrown drug major, Aurobindo Pharma today said it has received a final approval from the US health regulator for sale of Ceftazidime, used to treat respiratory infections, in the American market.
The company has bagged the final approval from US Food and Drug Administration for two variants of the drug, it said in a filing to the Bombay Stock Exchange (BSE).
The two variants -- Ceftazidime injections in strengths of 500 mg, 1 gram, 2 gram and 6 gram -- are used to treat infections caused by susceptible gram like septicemia, lower respiratory tract infections and abdominal cavity.
The two variants are generic equivalents to GlaxoSmithKilne's product 'Fortaz', with a market size of $30 million in the US.
The company currently has 89 final approvals from the US FDA for its new drugs.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app